Chemo combination promising for multiple myeloma

Chemo combination promising for multiple myeloma
For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.

Sagar Lonial, M.D., of the Winship Cancer Institute at Emory University in Atlanta, and colleagues conducted a phase I study to evaluate the dose-limiting toxicities and response rates associated with elotuzumab, , and low-dose dexamethasone treatment in 28 patients with relapsed or refractory multiple myeloma (median, three prior therapies). Patients were treated with 5, 10, or 20 mg/kg elotuzumab, plus lenalidomide and dexamethasone.

The researchers found no dose-limiting toxicities up to the maximum 20-mg/kg dose of elotuzumab. Neutropenia (36 percent) and thrombocytopenia (21 percent) were the most frequently reported grade 3 or 4 toxicities. Two serious infusion reactions, including one grade 4 anaphylactic reaction and one grade 3 stridor, occurred in two patients during the first treatment cycle. A total of 82 percent of patients exhibited objective responses. For patients treated until disease progression, after a median of 16.4 months follow-up, the median time to progression was not reached for patients in the 20-mg/kg cohort.

"The combination of elotuzumab, lenalidomide, and dexamethasone appears to be active, with results from this phase I study suggesting enhanced efficacy over lenalidomide and low-dose alone," the authors write. "Further validation of the dose, safety, and efficacy in larger patient populations is warranted and underway."

More information: doi: 10.1200/JCO.2011.37.2649

add to favorites email to friend print save as pdf

Related Stories

Multiple myeloma clinical trial closes early

Apr 05, 2007

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose ...

Recommended for you

Gene test aids cancer profile

5 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

22 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.